Best Peptides for Weight Loss

The most effective peptides for weight loss available in the UAE in 2026 span three mechanism classes: GLP-1/GIP dual agonists (tirzepatide), investigational triple agonists (retatrutide), mitochondrial metabolic regulators (MOTS-C), and growth hormone-related compounds (AOD 9604, somatropin).

Peptide	Mechanism	Best-fit goal	UAE status (2026)
Tirzepatide	GLP-1 + GIP dual agonism	Sustained fat loss, appetite control	Prescribed via clinics
Retatrutide	GLP-1 + GIP + glucagon triple agonism	Maximum weight reduction	Investigational only
MOTS-C	AMPK activation, mitochondrial signalling	Insulin sensitivity, fat oxidation	Research peptide
AOD 9604	GH fragment, peripheral lipolysis	Targeted fat loss support	Unverified regulatory status
Somatropin	Recombinant GH	Lean mass preservation	Clinic-prescribed, off-label weight use unverified

Tirzepatide delivered a mean 20.9% body-weight reduction at 72 weeks in SURMOUNT-1 (15 mg weekly, adults without diabetes); retatrutide reached approximately 24.2% at 48 weeks in phase 2 trials. No single peptide suits every metabolic profile. The sections below map each option to specific goals, dosing formats available in the UAE, and honest safety caveats.

Key Takeaways

• Tirzepatide is the most evidence-backed option, with 20.9% mean weight loss at 72 weeks and clinic availability in the UAE.
• Retatrutide shows greater early weight loss (24.2% at 48 weeks) but remains investigational with no MOHAP approval.
• MOTS-C works through mitochondrial efficiency rather than appetite suppression; human obesity trial data are absent.
• AOD 9604 targets peripheral fat mobilisation without growth hormone effects; onset is slower than GLP-1 agonists.
• Somatropin preserves lean mass during caloric deficit but carries documented risks including fluid retention and insulin resistance.
• No peer-reviewed stacking protocol exists for peptide combinations in humans.
• All compounds except tirzepatide operate outside approved UAE therapeutic indications.

Why Peptides for Weight Loss? Mechanism Overview

Weight-loss peptides target distinct biological pathways: appetite and glucose regulation via GLP-1 receptor agonism, enhanced insulin sensitivity via GIP co-agonism, increased energy expenditure via glucagon agonism, and improved metabolic efficiency via mitochondrial signalling. Which pathway matters most depends on your metabolic profile, that's the practical starting point for any peptide decision.

GLP-1 Receptor Agonism: Appetite and Glucose Control

GLP-1 (glucagon-like peptide-1) receptor agonists reduce appetite by slowing gastric emptying and signalling satiety centres in the hypothalamus. In SURMOUNT-1, tirzepatide's GLP-1 component contributed to a mean 20.9% body-weight reduction at 72 weeks on 15 mg weekly. GLP-1 agonism also lowers post-meal glucose spikes, which reduces the insulin-driven fat-storage signal that follows high-carbohydrate meals.

GIP Co-Agonism: Insulin Sensitivity and Fat Tissue Response

Adding GIP (glucose-dependent insulinotropic polypeptide) receptor agonism to GLP-1 activity produces greater weight loss than GLP-1 alone. Cross-trial comparisons from 2023 peer-reviewed analyses show that dual GLP-1/GIP agonism with tirzepatide yields roughly 5–6 percentage points more mean weight loss than semaglutide (GLP-1 monotherapy) at comparable timepoints. GIP receptors are expressed in adipose tissue, and their activation appears to improve how fat cells respond to insulin rather than simply suppressing appetite further.

Glucagon Agonism: Raising Resting Metabolic Rate

Glucagon receptor agonism is the third layer added by retatrutide, a triple agonist still under clinical investigation. Glucagon stimulates hepatic glucose output and increases thermogenesis, with mechanistic data suggesting a 5–10% rise in resting metabolic rate. Phase 2 data for retatrutide at 12 mg weekly showed approximately 24.2% mean weight loss at 48 weeks in adults without diabetes. 2023 comparative pharmacology reviews attribute this partly to the added energy-expenditure component.

Mitochondrial Peptides: Metabolic Efficiency

MOTS-C is a mitochondria-derived peptide encoded within mitochondrial 12S rRNA. It activates AMPK (adenosine monophosphate-activated protein kinase), increases skeletal-muscle glucose uptake, and enhances fatty-acid oxidation, improving insulin sensitivity in rodent models of diet-induced obesity. Unlike the receptor agonists above, MOTS-C does not suppress appetite directly; its role is improving how efficiently cells use fuel. Human obesity trial data remain pre-clinical as of 2024, so MOTS-C sits firmly in the research-peptide category.

None of these peptides carry MOHAP (Ministry of Health and Prevention) approval specifically for weight loss in the UAE. Tirzepatide is prescribed by some clinics for metabolic indications; the others operate in investigational or unverified regulatory territory. That distinction matters before any purchase decision.

Tirzepatide: Dual GLP-1/GIP Agonist, Dosing & Formats in UAE

Tirzepatide is a dual GLP-1 and GIP receptor agonist that reduces body weight by simultaneously suppressing appetite through GLP-1 signalling and improving insulin-stimulated glucose disposal through GIP receptor activation, producing greater fat loss than GLP-1 monotherapy in cross-trial comparisons.

How the Dual Mechanism Differs from Single GLP-1 Agonists

GLP-1 receptor agonism slows gastric emptying and reduces caloric intake via hypothalamic satiety pathways. GIP receptor co-agonism adds a separate layer: it enhances insulin secretion in a glucose-dependent manner and appears to reduce adipocyte lipid accumulation directly. 2023 comparative pharmacology reviews conclude that dual agonism yields greater average weight reduction than GLP-1 alone. In SURMOUNT-1, adults with obesity but without type 2 diabetes receiving tirzepatide 15 mg weekly achieved approximately 20.9% mean weight loss at 72 weeks, compared with roughly 3.1% on placebo. The 10 mg group reached approximately 19.5% at the same timepoint. Appetite suppression typically becomes noticeable within two to four weeks of initiating treatment, though meaningful weight change accumulates over months.

Dosing Progression

The standard titration begins at 2.5 mg weekly for four weeks, then increases in 2.5 mg increments every four weeks as tolerated, targeting a maintenance dose of 10 mg or 15 mg weekly. This gradual escalation is designed to reduce gastrointestinal side effects, primarily nausea, diarrhoea, and vomiting, which are the most commonly reported adverse events in the tirzepatide safety profile.

Pen Formats Available in the UAE

The table below summarises the two pen formats currently referenced for UAE research use.

Format	Doses per pen	Weeks at weekly dosing	Typical research use case
30-dose pen	30	~30 weeks	Standard titration through to maintenance phase
60-dose pen	60	~60 weeks	Extended protocols; fewer pen changes during longer studies

A 30-dose pen covers a single continuous titration cycle from 2.5 mg through to a stable maintenance dose without interruption. The 60-dose format suits longer research timelines where consistency of supply matters.

Regulatory Status in UAE

Tirzepatide is prescribed by some Dubai obesity clinics for metabolic indications, treated in practice similarly to semaglutide. No MOHAP approval specifically for weight loss has been confirmed in accessible 2024–2026 sources, and compounded or research-grade versions sit outside licensed pharmacy supply. Anyone considering tirzepatide in the UAE should obtain it through a licensed clinic rather than unverified import channels. A 2025 MHRA (Medicines and Healthcare products Regulatory Agency) enforcement action in the UK resulted in the confiscation of 2,000 doses of illegally imported weight-loss drugs labelled as tirzepatide and retatrutide, which illustrates the regulatory risk of grey-market procurement.

Retatrutide: Triple Agonist (GLP-1/GIP/Glucagon), Next-Generation Option

Retatrutide activates three receptors simultaneously: GLP-1, GIP, and glucagon. It is the most mechanistically comprehensive weight-loss peptide currently in clinical development, and early phase 2 data suggest it produces greater average weight reduction than either GLP-1 monotherapy or GLP-1/GIP dual agonism.

How Triple Agonism Differs from Tirzepatide

Tirzepatide targets GLP-1 and GIP receptors, suppressing appetite and improving insulin sensitivity. Retatrutide adds glucagon receptor agonism on top of that. Glucagon receptor activation increases hepatic glucose output and, more relevantly for weight loss, raises resting energy expenditure. Comparative pharmacology analyses from 2023 estimate this adds roughly 5–10% above the energy expenditure achieved by GLP-1/GIP agonism alone. The net effect is a peptide that simultaneously reduces caloric intake, improves insulin signalling, and accelerates fat oxidation through distinct receptor pathways.

Phase 2 data published in 2023 showed adults with obesity receiving retatrutide 12 mg weekly achieved approximately 24.2% mean weight loss at 48 weeks, compared with roughly 20.9% for tirzepatide 15 mg at 72 weeks in SURMOUNT-1. These are cross-trial comparisons, not head-to-head results, and should be read as directional rather than definitive. Retatrutide is still under clinical investigation; it is not routinely dispensed through Dubai pharmacies and is available only via research pathways.

Pen Formats Available in the UAE

The retatrutide pen range currently covers two capacities suited to different protocol lengths.

Format	Dose per injection	Total injections	Approximate research timeline
32-dose pen	8 mg	32	~32 weeks at weekly dosing
64-dose pen	16 mg	64	~64 weeks; suited to extended titration

The 32-dose pen at 8 mg covers a standard titration and early maintenance window. The 64-dose pen at 16 mg provides extended capacity for longer research protocols where supply continuity matters.

Positioning Relative to Tirzepatide

Retatrutide is earlier in its development cycle than tirzepatide, which means its long-term safety profile is less characterised. The side-effect pattern observed in phase 2, nausea, diarrhoea, vomiting, and a noted increase in resting heart rate, broadly mirrors the GLP-1/GIP class, with the glucagon component adding the heart rate signal as a distinguishing feature. Anyone in the UAE considering retatrutide should treat it as a research-stage compound and engage only through a licensed clinic rather than unverified import channels.

MOTS-C: Mitochondrial Peptide for Metabolic Efficiency

MOTS-C is a 16-amino-acid peptide encoded within mitochondrial 12S rRNA that improves insulin sensitivity and fat oxidation through AMPK activation and mitochondrial-nuclear signalling, without directly suppressing appetite.

Property	Detail
Mechanism	AMPK activation, mitochondrial-nuclear communication, improved glucose uptake
Primary effect	Enhanced fat oxidation, insulin sensitivity, metabolic flexibility
Appetite suppression	None, works via energy metabolism, not satiety signalling
UAE format	32-dose pen
Research stage	Preclinical and early human studies; no large obesity randomised controlled trial (RCT) completed
Common stack	Paired with tirzepatide or retatrutide for combined appetite and metabolic effect

How MOTS-C Works at the Cellular Level

Under metabolic stress, MOTS-C translocates from the mitochondria to the nucleus, where it modulates genes involved in the folate cycle and de novo purine biosynthesis, shifting cellular priority away from anabolic growth and toward improved insulin signalling. Downstream, AMPK activation increases skeletal-muscle glucose uptake and upregulates fatty-acid oxidation pathways. In rodent models of diet-induced obesity, systemic MOTS-C administration improved glucose tolerance and reduced adiposity alongside measurable increases in fat oxidation during metabolic challenge.

2024 mechanistic work further identified modulation of inflammatory signalling and adipokine profiles as contributing factors, suggesting MOTS-C acts as a stress-responsive, hormone-like regulator of metabolic flexibility rather than a simple lipolytic agent. These findings remain preclinical; no large-scale human obesity trial has been completed as of 2026.

Why It Differs from GLP-1-Class Peptides

GLP-1 and dual/triple agonists reduce body weight primarily by cutting caloric intake through appetite suppression and slowed gastric emptying. MOTS-C targets the other side of the energy equation: how efficiently cells utilise the fuel already available. This makes it conceptually complementary to appetite-suppressing peptides rather than a direct substitute.

The rationale for stacking MOTS-C with a GLP-1/GIP agonist is to simultaneously reduce caloric intake and improve mitochondrial efficiency and insulin sensitivity, though no peer-reviewed human trial has validated a specific combined protocol as of 2026. Any stacking approach should be treated as experimental and managed through a licensed UAE clinic.

Side-Effect Profile and Research Limitations

Published studies report a relatively mild tolerability profile for MOTS-C: transient injection-site discomfort and occasional fatigue or headaches are the most commonly noted adverse events. Robust 2024–2026 human safety datasets in obesity populations do not yet exist, so broader tolerability claims remain unverified. MOTS-C carries no MOHAP approval for therapeutic use in the UAE, placing it in the same research-peptide category as AOD 9604.

AOD 9604: Growth Hormone Fragment for Selective Fat Loss

AOD 9604 is a synthetic C-terminal fragment of human growth hormone (amino acids 176–191) that triggers lipolysis in adipocytes without activating growth hormone receptors, meaning it carries no risk of stimulating tissue growth or worsening insulin resistance.

Feature	Detail
Peptide class	GH fragment (C-terminal, aa 176–191)
Primary mechanism	β3-adrenergic receptor activation → lipolysis
Typical daily dose	300–600 mcg (subcutaneous injection)
Onset timeline	4–8 weeks for measurable fat-loss effect
Growth hormone effect	None, does not raise IGF-1 or GH levels
Glucose metabolism impact	Neutral, no hyperglycaemia risk reported
UAE regulatory status	Research peptide; no MOHAP therapeutic approval
Common use pattern	Adjunct to GLP-1 agonists such as tirzepatide

How the Mechanism Differs from GLP-1 Agonists

AOD 9604 acts directly on adipocyte β3-adrenergic receptors, stimulating the release of stored fatty acids for oxidation. This is a peripheral, tissue-specific pathway with no central appetite component, which is precisely why it does not replicate the broad metabolic effects of GLP-1/GIP agonists. Animal model data show fat oxidation increases of approximately 25% with AOD 9604 administration, though these findings have not been reproduced in large-scale human obesity trials as of 2026.

Why the Onset Is Slower

Because AOD 9604 works through lipolytic mobilisation rather than appetite suppression, users do not experience the rapid caloric-deficit effect that GLP-1 agonists produce within the first two weeks. The 4–8 week onset reflects the time required for sustained β3-adrenergic stimulation to produce measurable changes in body composition. This makes it a poor standalone option for anyone seeking rapid weight reduction, but a plausible adjunct for those already on a GLP-1 or triple-agonist protocol such as retatrutide who want to target residual adipose tissue without adding appetite-suppressing load.

Availability and Limitations in the UAE

AOD 9604 holds no MOHAP approval for therapeutic use in the UAE and is classified as a research peptide, placing it in the same regulatory category as MOTS-C. Supply is available through research-peptide channels, but quality control and sterility standards vary significantly between suppliers. The clinical trial evidence base is substantially thinner than that supporting tirzepatide or semaglutide, so any use should be treated as experimental and supervised through a licensed UAE clinic rather than self-administered.

Somatropin (HGH): Supporting Lean Mass & Metabolic Recovery

Somatropin is recombinant human growth hormone (rhGH) that supports weight loss indirectly by preserving lean muscle mass, raising resting metabolic rate, and improving body composition during a caloric deficit. This makes it a practical adjunct to GLP-1 or triple-agonist protocols rather than a primary fat-loss agent.

Attribute	Detail
Mechanism	Stimulates lipolysis, preserves lean mass, raises resting metabolic rate ~5–10%
Typical metabolic dosing	2–4 IU daily, 5–6 days per week
UAE pen formats	Body Pharm 40 IU pen; Body Pharm 100 IU pen
40 IU pen capacity	40 daily injections at 1 IU each
100 IU pen capacity	Extended use; 25–50 daily injections at 2–4 IU each
Storage	Refrigerated (2–8°C); limited room-temperature stability once in use
Regulatory status	Approved for GH deficiency; off-label weight-loss use is not a MOHAP-sanctioned indication

Why GLP-1 Users Specifically Consider It

GLP-1 and GIP/GLP-1 agonists such as tirzepatide produce rapid caloric deficits, but aggressive weight loss at that pace carries a documented risk of lean mass reduction alongside fat loss. Somatropin counters this by stimulating protein synthesis and preferentially directing the body toward adipose tissue for fuel. Endocrine practice guidelines note that rhGH raises resting metabolic rate by approximately 5–10% in adults with GH deficiency, with the mechanism centred on increased lipolysis and improved substrate utilisation.

Dosing Format and Pen Capacity in the UAE

The 2–4 IU daily range used for metabolic support sits well below the doses associated with performance misuse, which is where the documented adverse-effect profile, fluid retention, joint pain, insulin resistance, and carpal tunnel symptoms, becomes clinically significant. At 2 IU daily on a five-day-per-week schedule, a 40 IU pen covers approximately four weeks; the 100 IU pen extends that to roughly ten weeks, making it the more cost-efficient format for sustained protocols. Users on retatrutide or tirzepatide who add somatropin should do so under endocrinologist supervision, given the interaction between rhGH and insulin sensitivity. This concern compounds when GLP-1 agonists are already modulating glucose metabolism.

Regulatory and Safety Framing

Somatropin is a controlled prescription medicine in the UAE, approved for diagnosed GH deficiency rather than cosmetic weight loss. Any use outside that indication is off-label, and the risk profile at higher doses is well-characterised enough that self-administration without clinical oversight carries meaningful safety exposure. Specific 2026 MOHAP documentation on pen-format import rules for the 40 IU and 100 IU formats is not publicly available, so confirm current import and dispensing status directly with a licensed UAE clinic before sourcing.

Comparison Table: Weight-Loss Peptides in UAE (2026)

The five peptides covered in this guide differ substantially across mechanism, research maturity, and UAE availability. The table below maps each one against the criteria most relevant to a UAE buyer in 2026.

Peptide	Mechanism	Typical Dosing	Pen Formats in UAE	Expected Weight Loss	Onset Timeline	Best For	Research Status
Tirzepatide	GLP-1 / GIP dual agonism, appetite suppression + insulin sensitisation	5–15 mg weekly (titrated)	30-dose and 60-dose pens	~20.9% at 72 weeks (15 mg, SURMOUNT-1)	Meaningful loss by week 12–16; plateau near week 52–72	Obesity with or without T2D; strongest efficacy data of approved options	Approved; extensive phase 3 data
Retatrutide	GLP-1 / GIP / glucagon triple agonism, appetite + energy expenditure + lipolysis	4–12 mg weekly (phase 2 doses)	32-dose and 64-dose pens	~24.2% at 48 weeks (12 mg, phase 2)	Early signal by week 8–12; steep curve through week 36	Individuals seeking maximum fat loss; research-pathway access	Investigational; no MOHAP commercial registration
MOTS-C	Mitochondria-derived peptide; AMPK activation, improved insulin sensitivity and fatty-acid oxidation	5–10 mg per injection, 2–3x weekly (research dosing)	Vial format; no approved UAE pen	Pre-clinical fat-loss data only; no human obesity trial figures available	Metabolic markers improve in rodent models within 4–8 weeks	Adjunct metabolic support; insulin-resistant profiles	Early research; no human obesity RCTs
AOD 9604	GH fragment (hGH 176–191); stimulates lipolysis, inhibits lipogenesis without IGF-1 activity	300–500 mcg daily (research dosing)	Vial format; no approved UAE pen	No robust human weight-loss percentage data available	Lipolytic effects observed in animal models; human timeline unverified	Targeted fat reduction research; not a standalone obesity therapy	Research-stage; limited recent human data
Somatropin (rhGH)	Recombinant GH; increases lipolysis and lean-mass preservation via IGF-1 and direct receptor activation	2–4 IU daily (metabolic support range)	40 IU and 100 IU pens	5–10% body-fat reduction in GH-deficient adults	Measurable body-composition shift at 3–6 months	GH-deficient patients; lean-mass preservation during deficit	Approved for GH deficiency; off-label weight-loss use is unverified

Reading the Table

Cross-trial weight-loss percentages are not directly comparable. SURMOUNT-1 ran 72 weeks whilst the retatrutide phase 2 ran 48 weeks, and populations differed. Treat the figures as directional benchmarks rather than head-to-head rankings. MOTS-C and AOD 9604 lack human obesity trial data entirely, so those rows reflect mechanism and research-setting dosing only.

How to Choose: Matching Peptides to Your Goals

Your primary metabolic goal determines which peptide, or combination, is worth researching. Each compound targets a distinct physiological pathway and carries a different evidence burden.

If Appetite Suppression Is Your Primary Goal

Tirzepatide and retatrutide are the strongest candidates here. Tirzepatide's dual GLP-1/GIP agonism produced ~20.9% mean weight loss at 72 weeks in SURMOUNT-1 (15 mg weekly, non-diabetic adults). Retatrutide's additional glucagon agonism pushed that figure to ~24.2% at 48 weeks in its phase 2 trial. Both compounds show measurable appetite reduction within 2–4 weeks of initiation. Retatrutide remains investigational in the UAE with no commercial MOHAP registration, so access is limited to approved trial or special-access pathways.

If Metabolic Efficiency and Exercise Performance Matter

MOTS-C is the research-stage option to consider. It activates AMPK, increases skeletal-muscle glucose uptake, and enhances fatty-acid oxidation. Effects are documented in 2023 rodent models of diet-induced obesity. Human data remain limited, and onset in research settings is estimated at 4–6 weeks. MOTS-C is best positioned as a metabolic adjunct rather than a standalone weight-loss agent.

If Selective Fat Reduction Is the Goal

AOD 9604 targets lipolysis via the hGH 176–191 fragment without triggering IGF-1 activity, making it theoretically useful for localised fat reduction research. Animal-model data show lipolytic effects, but human timeline data are unverified. Research dosing runs 300–500 mcg daily, with effects observed over 4–8 weeks in pre-clinical settings.

If Preserving Lean Mass During a Caloric Deficit Is the Priority

Somatropin (rhGH) is the most established option for lean-mass preservation, with body-composition shifts measurable at 3–6 months in GH-deficient adults. Its use for cosmetic weight loss is off-label and carries a well-documented side-effect profile including fluid retention, insulin resistance, and joint pain. It works best as an adjunct, not a primary fat-loss agent.

Stacking: Rationale and Safety Caveats

No peer-reviewed stacking protocol exists for these combinations in humans. The conceptual rationale for common research stacks is:

• Tirzepatide + MOTS-C, pairs central appetite suppression with peripheral mitochondrial metabolic improvement. Onset mismatch (2–4 weeks vs. 4–6 weeks) means effects are sequential rather than simultaneous.
• Retatrutide + somatropin, triple agonism for fat loss combined with lean-mass preservation during deficit. Somatropin's insulin-resistance risk may partially counteract retatrutide's glycaemic benefits.
• AOD 9604 + tirzepatide, targets both central satiety and peripheral lipolysis pathways. No human data confirm additive fat-loss benefit beyond tirzepatide alone.

Major clinical obesity guidelines as of 2024–2026 caution against unapproved peptide combinations and favour monotherapy or well-studied dual/triple agonists. Any stacking approach sits outside approved indications in the UAE, increases the complexity of side-effect attribution, and should only be considered under direct medical supervision.

Dosing Protocols & Pen Formats: What's Available in UAE

Pen format and injection frequency vary significantly across these peptides. Matching the right format to your protocol is as practical a decision as choosing the peptide itself.

Peptide	Common Format	Dose per Injection	Frequency	Typical Duration
Tirzepatide	30-dose pen	2.5 mg → 15 mg (titrated)	Once weekly	30 weeks (30-dose); 60 weeks (60-dose)
Retatrutide	32-dose pen (8 mg total) / 64-dose pen (16 mg total)	0.25 mg → 2.5 mg (titrated)	Once weekly	~8 weeks (32-dose); ~16 weeks (64-dose)
MOTS-C	32-dose pen	100–200 mcg	Daily or 5x/week	6–8 weeks per cycle
AOD 9604	Vial (reconstituted)	300–600 mcg	Daily	8–12 weeks typical
Somatropin	40 IU pen / 100 IU pen	2–4 IU	5–6 days/week	Ongoing under medical supervision

Tirzepatide Titration

The standard titration for tirzepatide runs in four-week blocks: 2.5 mg weekly for weeks 1–4, stepping to 5 mg for weeks 5–8, then advancing toward 10–15 mg from week 9 onward depending on tolerability. The 30-dose pen covers one full titration cycle through to a maintenance dose; the 60-dose pen extends this for longer study periods. Slower titration reduces the GI side-effect burden documented in post-marketing safety data.

Retatrutide Titration

Retatrutide starts at 0.25 mg weekly, titrating to 2.5 mg over approximately four weeks in the phase 2 protocol that recorded up to 24.2% mean weight loss at 48 weeks. The 32-dose pen (8 mg total) suits an initial titration and early maintenance phase; the 64-dose pen (16 mg total) extends coverage. Because retatrutide remains investigational in the UAE, these formats are not available through standard pharmacy channels.

MOTS-C and AOD 9604 Formats

MOTS-C is supplied as a 32-dose pen delivering 100–200 mcg per injection, dosed daily or five times per week. AOD 9604 arrives as a lyophilised vial requiring reconstitution; once mixed with bacteriostatic water, refrigerated stability is approximately 21–30 days. Daily subcutaneous injections of 300–600 mcg are the standard research dosing range.

Somatropin Pen Formats

Somatropin pens in 40 IU and 100 IU capacities deliver 2–4 IU per injection across five to six days per week. The 100 IU pen reduces reconstitution frequency for longer cycles. Refrigeration is required throughout; room-temperature stability once in use is limited and varies by brand. Any somatropin use for weight management rather than confirmed GH deficiency is off-label and carries the insulin-resistance and fluid-retention risks documented in endocrine practice guidelines.

Regulatory Status & Safety Considerations in UAE

No peptide covered in this guide carries MOHAP approval specifically for weight loss as of 2026. The table below maps each compound to its current regulatory position in the UAE and globally.

Peptide	UAE (MOHAP) Status	Global Approvals (2026)	Approved Indication
Tirzepatide	Unverified; clinical use reported at Dubai obesity clinics	US FDA (2023), EU (2023)	Type 2 diabetes; obesity (US/EU)
Retatrutide	Investigational only; no commercial registration	US FDA (2024); EU pending	Obesity (US only, investigational elsewhere)
MOTS-C	Research peptide; no MOHAP registration identified	None	No approved indication
AOD 9604	Research peptide; no MOHAP registration identified	None	No approved indication
Somatropin	Used clinically for GH deficiency; weight loss is off-label	Widely approved globally	GH deficiency, paediatric growth disorders

Side Effect Profiles by Class

GLP-1/GIP agonists such as tirzepatide produce predominantly gastrointestinal effects: nausea, diarrhoea, vomiting, constipation, and dyspepsia, with rare but serious risks including pancreatitis and potential thyroid C-cell changes. Retatrutide shares this GI profile and additionally shows increased heart rate in phase 2 data; long-term tolerability remains under investigation.

Somatropin carries a well-characterised risk profile: fluid retention, joint and muscle pain, carpal tunnel syndrome, insulin resistance, and in misuse scenarios, cardiometabolic complications. MOTS-C shows transient injection-site discomfort and occasional fatigue in small human studies, but robust 2024–2026 human safety datasets do not yet exist.

Possession and Import in the UAE

Importing unapproved peptides into the UAE sits in a legal grey area. A 2025 MHRA enforcement action in the UK resulted in confiscation of 2,000 doses of illegally imported tirzepatide and retatrutide, signalling that Gulf regulators face similar pressures. Verify current MOHAP import rules directly before ordering any compound not dispensed through a licensed UAE pharmacy. Consult a UAE-registered endocrinologist or obesity physician before initiating any peptide protocol.

Where to Buy Peptides in UAE: Sourcing & Verification

Sourcing peptides in the UAE requires prioritising suppliers with documented batch-testing records, verifiable storage compliance, and transparent product provenance rather than simply the lowest price.

Established Suppliers in the Region

Two suppliers with a track record in the Gulf research-peptide market are Body Pharm (operating since 2015) and HD Labs (operating since 2010). Both provide lyophilised vials and pen formats for compounds including tirzepatide and retatrutide. JCSG provides product information and links to verified product pages but does not sell directly; use it as a reference point to confirm product specifications before purchasing elsewhere.

What to Verify Before Any Purchase

Before committing to a supplier, confirm the following:

• Batch-testing documentation, request a certificate of analysis showing HPLC (high-performance liquid chromatography) or mass spectrometry verification for each batch, not a generic brand-level certificate.
• Storage chain, lyophilised peptides should be stored at −20°C unopened and transferred to 2–8°C after reconstitution. Prefilled pens require continuous refrigeration at 2–8°C.
• Expiry dating, unopened lyophilised vials typically carry a 24–36 month shelf life from manufacture. Once reconstituted with bacteriostatic water, the working solution is stable for approximately 21–30 days at 2–8°C.
• Light protection, amber vials or opaque packaging are standard. Clear vials with no UV protection are a quality red flag.

Spotting Counterfeit Products

A 2025 MHRA enforcement action resulted in the confiscation of 2,000 doses of illegally imported tirzepatide and retatrutide, confirming that counterfeit and mislabelled weight-loss peptides circulate in the Gulf supply chain. Signs of a suspect product include missing batch numbers, inconsistent label fonts, no cold-chain packaging on delivery, and prices significantly below market rate. Cross-reference any supplier's batch number against their published certificate of analysis before use.

FAQ: Common Questions About Weight-Loss Peptides

Six questions come up repeatedly among UAE buyers. The table below gives direct answers, with fuller detail beneath each entry.

Question	Short Answer
How fast do peptides work?	GLP-1 agonists: 2–4 weeks; MOTS-C: 4–6 weeks; AOD 9604: 4–8 weeks
Can I stack peptides?	Yes, but no peer-reviewed stacking protocols exist yet
Are peptides safe?	Side-effect profiles vary; most are research-stage; medical supervision required
How much weight can I lose?	Tirzepatide ~20.9% at 72 weeks; retatrutide ~24.2% at 48 weeks (phase 2)
Do I need to diet?	Yes, peptides amplify a caloric deficit; they do not replace one
What does it cost in the UAE?	Tirzepatide 30-dose: approx. AED 800–1,200; retatrutide 32-dose: approx. AED 1,200–1,800 (2026 estimates)